Incyte Signs Database Deal With Novo Nordisk
Incyte Pharmaceuticals of the USA has signed an agreement with the Danish insulin and diagnostics product group Novo Nordisk A/S and its subsidiary ZymoGenetics, whereby the Danish firm will have access to Incyte's DNA sequence and gene expression database. Novo will pay access fees and make royalty and milestone payments on drug products developed under license to Incyte technology and database information.
Novo president Bruce Carter said this was another step towards developing the company's technology base to fit the health care strategy launched last December, but one missing element has been access to "a world class database that contains human gene sequences." He added that the database was needed to identify targets for drug discovery that will be therapeutically useful in the firm's core business areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze